Mogy Joel R Investment Counsel Inc. Purchases 1,010 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mogy Joel R Investment Counsel Inc. boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,324 shares of the company’s stock after buying an additional 1,010 shares during the period. IDEXX Laboratories makes up approximately 1.9% of Mogy Joel R Investment Counsel Inc.’s investment portfolio, making the stock its 18th largest position. Mogy Joel R Investment Counsel Inc. owned about 0.10% of IDEXX Laboratories worth $32,796,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth about $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new position in shares of IDEXX Laboratories in the second quarter worth about $36,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IDXX. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler reissued a “neutral” rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Barclays dropped their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $523.86.

IDEXX Laboratories Stock Down 2.2 %

Shares of IDXX opened at $419.26 on Tuesday. The stock’s 50-day moving average price is $423.24 and its two-hundred day moving average price is $457.45. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a market capitalization of $34.33 billion, a PE ratio of 40.43, a PEG ratio of 3.53 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.53 earnings per share. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.